贝飞达联合乳果糖治疗肝硬化后血清内毒素TNFα、IL-6的变化及预防自发性腹膜炎的临床意义

Changes of Serum Endotoximia,TNF-α and Interleukin-6 Levels and Effective in Preventing Spontaneous Bacterial Peritonitis after Treatment combined with Beifeida and Lactulose in Patients With Liver Cirrhosis

【目的】观察肝硬化患者应用贝飞达联合乳果糖治疗前后血清内毒素、TNFα、IL-6水平的变化以及自发性细菌性腹膜炎(SBP)的发生率,寻找一种能够更有效降低SBP发生的方法。【方法】100例肝硬化患者随机分成对照组(A组)和治疗组(B组),对照组50例,给予常规护肝利尿补充白蛋白治疗;治疗组50例,在常规治疗的基础上加服贝飞达+乳果糖联用,疗程3个月。【结果】对照组治疗前后血清内毒素及TNFα、IL-6水平无明显变化,治疗组治疗后血清内毒素及TNFα、IL-6明显下降,SBP发生率明显降低,与对照组比较差异有显著性。【结论】贝飞达联合乳果糖治疗肝硬化患者可有效的降低血浆中内毒素及TNFα、IL-6水平,明显降低SBP发生率。

To observe the changes of serum endotoxin and TNF-a,interleukin-6 levels before and after treatment combined with beifeida and Lactulose in patients with liver cirrhosis and to observe the incidence of spontaneous bacterial peritonitis（SBP） and to find a method that can more efficient to reduce the incidence of SBP. [Methods]100 hundred patients were included in the study. Patients in controll Group A （ n=50） were given conventional treatment such as protecting the liver, supplement human albumin and uragogue. Patients in treament Group B （ n = 50） were given both beifeida tid po and Lactulose bid po on the basis of conventional treatment for three months. [Results]Serum endotoxin , TNF-aand interleukin-6 levels in Group A were not significantly changed after treatment, but SBP incidence was higher than Group B. At Group B, serum endotoxin, TNF-α,interleukin-6 levels and SBP incidence significantly droped, the difference was significant at statistics as compared with Group A. [Conclusion] The treatment combined with beifeida and Lactulose can effectively reduce serum endotoxin,TNF-a and interleukin-6 levels, and also can significantly reduce the incidence of SBP.